INSULIN SENSITIZERS MARKET ANALYSIS

Insulin Sensitizers Market, By Type of Insulin Sensitizers (Thiazolidinediones (TZDs), Biguanides, Incretin-based therapies, Others), By Indication (Type 2 Diabetes, Prediabetes, Polycystic Ovary Syndrome (PCOS)), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

New product launches

In June 2021, U.S. Food and Drug Administration approved Wegovy (semaglutide) injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol) The FDA granted the approval to Novo Nordisk, one of the global biopharmaceutical company.

Acquisition and partnerships

On September 19, 2023, Novo Nordisk, one of the leading global healthcare company, announced its partnership with Aspen SA Operations (Pty) Ltd., one of the global specialty and branded multinational pharmaceutical company, to establish human insulin production in South Africa
In April 2022, Abbott, one of the global healthcare leader, CamDiab, a digital health and personalized medicine company, and Ypsomed, one of the leading developer and manufacturer of injection and infusion systems, announced that all are partnering to develop and commercialize an integrated automated insulin delivery (AID) system to lessen the burden of round-the-clock diabetes management for people with diabetes
In December 2022, Eli Lilly and Company, one of the global biopharmaceutical company, and EVA Pharma, a pharmaceutical company, announced collaboration to deliver a sustainable supply of high-quality, affordable human and analogue insulin to at least one million people living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are in Africa